Due to their broad regulation of pre- and post-synaptic excitability, and specifically, their potential to reduce glutamate release and subsequent downstream activation of mGluR5, GABAB agonists like arbaclofen have been explored as a potential FXS therapy (Berry-Kravis et al., 2012, 2017). The gene discussed is GRM5; the disease is fragile X syndrome.